Array's ARRY-797 meets Phase II pain endpoint

Array BioPharma Inc. (NASDAQ:ARRY) said oral ARRY-797 met the primary endpoint of reducing mean WOMAC pain subscale scores from baseline to day 28 vs. placebo in a Phase II trial to treat osteoarthrit...